Catalyst

Slingshot members are tracking this event:

Amgen (AMGN) and UCB Announce Phase III FRAME Results Evaluating Romosozumab in Postmenopausal Women with Osteoporosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AMGN

100%
UCB

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 18, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase Iiii Frame Results, Romosozumab, Postmenopausal Women, Osteporosis